Nektar Therapeutics Inc
$
32.15
0.13 (0.41%)
| Volume: | 1,258,671 | Avg Vol (1m): | 1,616,099 |
| Market Cap $: | 5.60 Bil | Enterprise Value $: | 4.46 Bil |
| P/E (TTM): | 9.15 | P/B: | 3.43 |
| Earnings Power Value | -23.47 |
| Net Current Asset Value | 5.51 |
| Tangible Book | 8.96 |
| Projected FCF | 9.01 |
| Median P/S Value | 62.19 |
| Graham Number | 26.63 |
| Peter Lynch Value | 0 |
| DCF (FCF Based) | 0 |
| DCF (Earnings Based) | 0 |
YTD (-%)
Add to portfolio
Email alerts
Stock PDF
RSS
Website
Filings
Download Excel
Batch Download
Manual of Stocks™ Web
Manual of Stocks™
Manual of Stocks™ Web
Manual of Stocks™
Financial Strength : 8/10
GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
| Current | vs industry | vs history | |
|---|---|---|---|
| Cash-to-Debt | 5.61 |
Cash-To-Debt ranked
lower than
58.81%
of
1078
companies
in the
Biotechnology
industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
NKTR:
5.61
Ranked among companies with meaningful Cash-To-Debt only.
|
Cash-To-Debt range over the past 10 years
Min: 0.72, Med: 1.57, Max: 389.59
Current: 5.61
|
| Equity-to-Asset | 0.75 |
Equity-to-Asset ranked
higher than
68.15%
of
763
companies
in the
Biotechnology
industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
NKTR:
0.75
Ranked among companies with meaningful Equity-to-Asset only.
|
Equity-to-Asset range over the past 10 years
Min: -0.21, Med: 0.36, Max: 0.92
Current: 0.75
|
| Debt-to-Equity | 0.15 |
Debt-to-Equity ranked
higher than
67.80%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
NKTR:
0.15
Ranked among companies with meaningful Debt-to-Equity only.
|
Debt-to-Equity range over the past 10 years
Min: -909.95, Med: 1.16, Max: 73.27
Current: 0.15
|
| Debt-to-EBITDA | 0.35 |
Debt-to-EBITDA ranked
higher than
82.65%
of
196
companies
in the
Biotechnology
industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
NKTR:
0.35
Ranked among companies with meaningful Debt-to-EBITDA only.
|
Debt-to-EBITDA range over the past 10 years
Min: -48.71, Med: -2.82, Max: 0.35
Current: 0.35
|
| Interest Coverage | 14.96 |
Interest Coverage ranked
lower than
80.60%
of
500
companies
in the
Biotechnology
industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
NKTR:
14.96
Ranked among companies with meaningful Interest Coverage only.
|
Interest Coverage range over the past 10 years
Min: 14.96, Med: 16.08, Max: 16.08
Current: 14.96
|
| Piotroski F-Score | 8 |
0
1
2
3
4
5
6
7
8
9
| |
| Altman Z-Score | 7.67 |
DISTRESS
GREY
SAFE
| |
| Beneish M-Score | 0.06 |
Not Manipulator
Manipulator
| |
| WACC vs ROIC % |
ROIC 161.24%
WACC 22.69%
| ||
Profitability & Growth : 7/10
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
| Current | vs industry | vs history | |
|---|---|---|---|
| Operating Margin % | 55.26 |
Operating Margin ranked
higher than
98.11%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
NKTR:
55.26
Ranked among companies with meaningful Operating Margin only.
|
Operating Margin range over the past 10 years
Min: -173.39, Med: -41.21, Max: 57.65
Current: 55.26
|
| Net Margin % | 55.65 |
Net Margin ranked
higher than
96.97%
of
792
companies
in the
Biotechnology
industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
NKTR:
55.65
Ranked among companies with meaningful Net Margin only.
|
Net Margin range over the past 10 years
Min: -211.67, Med: -63.99, Max: 57.09
Current: 55.65
|
| ROE % | 46.64 |
ROE ranked
higher than
99.70%
of
989
companies
in the
Biotechnology
industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
NKTR:
46.64
Ranked among companies with meaningful ROE only.
|
ROE range over the past 10 years
Min: -379.68, Med: -101.4, Max: 75.47
Current: 46.64
|
| ROA % | 35.12 |
ROA ranked
higher than
99.54%
of
1084
companies
in the
Biotechnology
industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
NKTR:
35.12
Ranked among companies with meaningful ROA only.
|
ROA range over the past 10 years
Min: -34.75, Med: -18, Max: 51.25
Current: 35.12
|
| ROC (Joel Greenblatt) % | 1323.99 |
ROC (Joel Greenblatt) ranked
higher than
98.94%
of
1036
companies
in the
Biotechnology
industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
NKTR:
1323.99
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
|
ROC (Joel Greenblatt) range over the past 10 years
Min: -182.91, Med: -108.42, Max: 1323.99
Current: 1323.99
|
| 3-Year Total Revenue Growth Rate | 72.90 |
3-Year Revenue Growth Rate ranked
higher than
60.98%
of
651
companies
in the
Biotechnology
industry.
Industry Max: 906.3, Med: 1.1, Min: -100
NKTR:
56.1
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
|
3-Year Revenue Growth Rate range over the past 10 years
Min: -31.6, Med: 10.3, Max: 62.2
Current: 56.1
|
» NKTR's 30-Y Financials
Financials (Next Earnings Date: 2019-08-08)
Guru Trades Click for details
Guru Trades in
SEC Filings
Gurus Latest Trades with NAS:NKTR
» Interactive Chart
Peter Lynch Chart
Business Description
| Industry | Biotechnology » Biotechnology   NAICS : 325412   SIC : 2834 |
| Compare | SZSE:002007 NAS:ASND BOM:532523 NAS:EXEL XAMS:GLPG NAS:ARRY SZSE:300347 NAS:AMRN NAS:ALKS TSE:4587 XBRU:ARGX HKSE:01530 HKSE:01548 NAS:UTHR SZSE:000990 SZSE:002252 XKRX:128940 NAS:NBIX LSE:BTG NAS:FGEN |
| Traded in other countries | ITH.Germany 0UNL.UK |
| Address | 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158 |
| Nektar Therapeutics Inc is a biopharmaceutical company that seeks to enable the development of new molecules to treat a number of therapeutic areas including oncology, pain, anti-infectives, and immunology. The company's research and development activities involve small-molecule drugs, peptides, and protein biologic drug candidates. The company decides on a candidate-by-candidate basis how far to advance clinical development and whether to commercialize products on its own, seek a partner, or pursue a combination of these approaches. Nektar's partnershipaims to fund continued clinical development, manage the regulatory filing process, and market and sell drugs in various geographies. | |
Ratios
| Current | vs industry | vs history | |
|---|---|---|---|
| PE Ratio (TTM) | 9.15 |
PE Ratio ranked
higher than
81.05%
of
248
companies
in the
Biotechnology
industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
NKTR:
9.15
Ranked among companies with meaningful PE Ratio only.
|
PE Ratio range over the past 10 years
Min: 8.51, Med: 12.22, Max: 432.33
Current: 9.15
|
| PE Ratio without NRI | 9.15 |
PE without NRI ranked
higher than
81.48%
of
243
companies
in the
Biotechnology
industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
NKTR:
9.15
Ranked among companies with meaningful PE without NRI only.
|
PE without NRI range over the past 10 years
Min: 8.51, Med: 12.22, Max: 432.33
Current: 9.15
|
| Price-to-Owner-Earnings | 9.13 |
Price-to-Owner-Earnings ranked
higher than
84.14%
of
145
companies
in the
Biotechnology
industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
NKTR:
9.13
Ranked among companies with meaningful Price-to-Owner-Earnings only.
|
Price-to-Owner-Earnings range over the past 10 years
Min: 8.65, Med: 49.62, Max: 141.1
Current: 9.13
|
| PB Ratio | 3.43 |
PB Ratio ranked
lower than
60.91%
of
962
companies
in the
Biotechnology
industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
NKTR:
3.43
Ranked among companies with meaningful PB Ratio only.
|
PB Ratio range over the past 10 years
Min: 1.97, Med: 10.76, Max: 1041.36
Current: 3.43
|
| PS Ratio | 4.94 |
PS Ratio ranked
higher than
60.47%
of
726
companies
in the
Biotechnology
industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
NKTR:
4.94
Ranked among companies with meaningful PS Ratio only.
|
PS Ratio range over the past 10 years
Min: 1.76, Med: 9.56, Max: 54.12
Current: 4.94
|
| Price-to-Free-Cash-Flow | 8.85 |
Price-to-Free-Cash-Flow ranked
higher than
82.89%
of
152
companies
in the
Biotechnology
industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
NKTR:
8.85
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
|
Price-to-Free-Cash-Flow range over the past 10 years
Min: 8.06, Med: 13.74, Max: 65.18
Current: 8.85
|
| Price-to-Operating-Cash-Flow | 8.60 |
Price-to-Operating-Cash-Flow ranked
higher than
82.38%
of
210
companies
in the
Biotechnology
industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
NKTR:
8.6
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
|
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 4.41, Med: 13.17, Max: 30.57
Current: 8.6
|
| EV-to-EBIT | 6.35 |
EV-to-EBIT ranked
higher than
75.86%
of
261
companies
in the
Biotechnology
industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
NKTR:
6.35
Ranked among companies with meaningful EV-to-EBIT only.
|
EV-to-EBIT range over the past 10 years
Min: -263.8, Med: -12.35, Max: 235.4
Current: 6.35
|
| EV-to-EBITDA | 6.25 |
EV-to-EBITDA ranked
higher than
72.24%
of
281
companies
in the
Biotechnology
industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
NKTR:
6.25
Ranked among companies with meaningful EV-to-EBITDA only.
|
EV-to-EBITDA range over the past 10 years
Min: -1854.2, Med: -10.45, Max: 243.9
Current: 6.25
|
| EV-to-Revenue | 3.76 |
EV-to-Revenue ranked
higher than
68.48%
of
771
companies
in the
Biotechnology
industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
NKTR:
3.76
Ranked among companies with meaningful EV-to-Revenue only.
|
EV-to-Revenue range over the past 10 years
Min: 1.5, Med: 8.8, Max: 54.1
Current: 3.76
|
| Current Ratio | 14.94 |
Current Ratio ranked
higher than
90.69%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
NKTR:
14.94
Ranked among companies with meaningful Current Ratio only.
|
Current Ratio range over the past 10 years
Min: 1, Med: 5.94, Max: 19.67
Current: 14.94
|
| Quick Ratio | 14.83 |
Quick Ratio ranked
higher than
90.78%
of
1074
companies
in the
Biotechnology
industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
NKTR:
14.83
Ranked among companies with meaningful Quick Ratio only.
|
Quick Ratio range over the past 10 years
Min: 0.96, Med: 5.87, Max: 19.55
Current: 14.83
|
| Days Inventory | 185.64 |
Days Inventory ranked
lower than
59.25%
of
481
companies
in the
Biotechnology
industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
NKTR:
185.64
Ranked among companies with meaningful Days Inventory only.
|
Days Inventory range over the past 10 years
Min: 93.11, Med: 142.98, Max: 185.64
Current: 185.64
|
| Days Sales Outstanding | 13.23 |
Days Sales Outstanding ranked
higher than
89.82%
of
668
companies
in the
Biotechnology
industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
NKTR:
13.23
Ranked among companies with meaningful Days Sales Outstanding only.
|
Days Sales Outstanding range over the past 10 years
Min: 5.46, Med: 24.79, Max: 57.61
Current: 13.23
|
| Days Payable | 173.20 |
Days Payable ranked
higher than
70.15%
of
536
companies
in the
Biotechnology
industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
NKTR:
173.2
Ranked among companies with meaningful Days Payable only.
|
Days Payable range over the past 10 years
Min: 25.29, Med: 43.25, Max: 173.2
Current: 173.2
|
Dividend & Buy Back
| Current | vs industry | vs history | |
|---|---|---|---|
| 3-Year Share Buyback Rate | -8.60 |
3-Year Share Buyback Rate ranked
higher than
70.83%
of
857
companies
in the
Biotechnology
industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
NKTR:
-8.6
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
|
3-Year Share Buyback Rate range over the past 10 years
Min: -21.5, Med: -8, Max: -0.7
Current: -8.6
|
Valuation & Return
| Current | vs industry | vs history | |
|---|---|---|---|
| Price-to-Tangible-Book | 3.59 |
Price-to-Tangible-Book ranked
lower than
53.69%
of
894
companies
in the
Biotechnology
industry.
Industry Max: 800, Med: 5.32, Min: 0.05
NKTR:
3.59
Ranked among companies with meaningful Price-to-Tangible-Book only.
|
Price-to-Tangible-Book range over the past 10 years
Min: 2.54, Med: 6.03, Max: 1833.33
Current: 3.59
|
| Price-to-Projected-FCF | 3.57 |
Price-to-Intrinsic-Value-Projected-FCF ranked
lower than
62.18%
of
193
companies
in the
Biotechnology
industry.
Industry Max: 117, Med: 3.12, Min: 0.09
NKTR:
3.57
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
|
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 3.4, Med: 3.8, Max: 5.15
Current: 3.57
|
| Price-to-Median-PS-Value | 0.52 |
Price-to-Median-PS-Value ranked
higher than
59.00%
of
678
companies
in the
Biotechnology
industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
NKTR:
0.52
Ranked among companies with meaningful Price-to-Median-PS-Value only.
|
Price-to-Median-PS-Value range over the past 10 years
Min: 0.2, Med: 1.14, Max: 5.55
Current: 0.52
|
| Price-to-Graham-Number | 1.21 |
Price-to-Graham-Number ranked
higher than
64.00%
of
200
companies
in the
Biotechnology
industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
NKTR:
1.21
Ranked among companies with meaningful Price-to-Graham-Number only.
|
Price-to-Graham-Number range over the past 10 years
Min: 1.19, Med: 1.45, Max: 73.33
Current: 1.21
|
| Earnings Yield (Joel Greenblatt) % | 15.74 |
Earnings Yield (Greenblatt) ranked
higher than
94.17%
of
1081
companies
in the
Biotechnology
industry.
Industry Max: 5000, Med: -7.73, Min: -10000
NKTR:
15.74
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
|
Earnings Yield (Greenblatt) range over the past 10 years
Min: -27.7, Med: -5.2, Max: 16.8
Current: 15.74
|
More Statistics
| Revenue (TTM) (Mil) $ | 1,183.53 |
| EPS (TTM) $ | 3.52 |
| Beta | 3.42 |
| Volatility % | 73 |
| 52-Week Range $ | 29.22 - 92.17 |
| Shares Outstanding (Mil) | 174.31 |
Analyst Estimate
Piotroski F-Score Details
| Piotroski F-Score | 8 |
| Positive ROA | Y |
| Positive CFROA | Y |
| Higher ROA yoy | Y |
| CFROA > ROA | Y |
| Lower Leverage yoy | Y |
| Higher Current Ratio yoy | Y |
| Less Shares Outstanding yoy | N |
| Higher Gross Margin yoy | Y |
| Higher Asset Turnover yoy | Y |